Cell-cycle targeted therapies (Q35618786)

9 August 2017

1 reference

title

Cell-cycle targeted therapies (English)

1 reference

9 August 2017

Charles Swanton

1

0 references

publication date

1 January 2004

1 reference

Lancet Oncology Commission

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

27-36

1 reference

Cell cycle control and cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

A Restriction Point for Control of Normal Animal Cell Proliferation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

New functional activities for the p21 family of CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Crystal structure of a gamma-herpesvirus cyclin-cdk complex

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Cyclin E-CDK2 is a regulator of p27Kip1.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Are p27 and p21 cytoplasmic oncoproteins?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

To cycle or not to cycle: a critical decision in cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

SSeCKS, a major protein kinase C substrate with tumor suppressor activity, regulates G(1)-->S progression by controlling the expression and cellular compartmentalization of cyclin D.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1)

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Chromosome 11q13 markers and D-type cyclins in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Cyclin E and survival in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

A gene-expression signature as a predictor of survival in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Structural basis for Chk1 inhibition by UCN-01

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Activation of the cell death program by inhibition of proteasome function

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

FR901228 causes mitotic arrest but does not alter microtubule polymerization

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01321-4

7 January 2021

10.1016/S1470-2045(03)01321-4

Identifiers

DOI

1 reference

9 August 2017

1 reference